Juniper Pharmaceuticals (Nasdaq: JNP) is a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women’s health. Our pipeline will initially leverage the 505(b)(2) regulatory pathway with new formulations of existing pharmaceuticals. We are leveraging in-house pharmaceutical development, clinical trial supply manufacturing, and analytical capabilities to advance an internal product pipeline, while also providing valuable intellectual property-related consultative services to our pharmaceutical industry customers. Future pipeline products will utilize our novel drug delivery technologies, including our proprietary bioadhesive delivery system (BDS) and a segmented intra-vaginal ring (IVR) developed in the laboratories of Dr. Robert Langer at the Massachusetts Institute of Technology and Dr. William Crowley at Massachusetts General Hospital and Harvard Medical School. Juniper is positioned for success with a highly experienced leadership team in combination with a strong balance sheet and positive cash flows to fund a proprietary pipeline for long term value creation. Visit us: http://www.juniperpharma.com/.
Alcami is a world-class supplier of comprehensive pharmaceutical development and manufacturing services headquartered in Wilmington, NC. Operating at seven sites in the United States and Europe, we provide flexible, transparent and innovative services to small and mid-size pharma and biotech companies by offering individualized and integrated services across Active Pharmaceutical Ingredients (APIs), Drug Product, Development Services, and Analytical Testing. We strive to be the most customer-focused and reliable partner built on safety, compliance, strong scientific expertise and leading technologies. Visit us: http://www.alcaminow.com/.
Fluid Air’s patent-pending PolarDryTM Spray Dryers utilizes revolutionary Electrostatic Technology, provides low temperature spray drying, near perfect encapsulation and selective agglomeration in the creation of particles. Years of development have proven that PolarDryTM technology has many advantages that include superior morphology, higher bulk density, longer shelf life, non-reactive processing, minimal emissions and low energy consumption. This new Technology will provide the means to make your formulation ideas a reality. Applications include API production where high temperature is a limiting factor, new avenues for drug delivery where perfect encapsulation is a must. Visit us: http://www.fluidairinc.com/.
iCeutica is a privately held pharmaceutical company focused on leveraging its proprietary SoluMatrix™ drug delivery technology for the creation of value-added branded pharmaceutical products, independently and in collaboration with our partners. SoluMatrix™ technology produces sub-micron sized crystalline drug particles with enhanced dissolution properties relative to conventional micronized material. This approach can lead to significant bioavailability enhancement in terms of increased AUC, more rapid absorption, decreased food effects, and lower pharmacokinetic variability. At present there are three US FDA-approved prescription drug products that incorporate SoluMatrix™ technology. iCeutica is based in the greater Philadelphia, PA area. Visit us: http://www.iceutica.com/
Absorption Systems supports pharmaceutical and medical device companies in identifying and overcoming ADMET barriers in development of drugs and medical devices. The company’s mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. Visit www.absorption.com to view our comprehensive contract services and applied research programs.
Interested In Working With Us? Download Our Sponsorship Prospectus.